title: A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus.
abstract: OBJECTIVE
  Drug-induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti-TNF therapies have been found to be associated with a lupus-like syndrome, which is clinically distinct from classical drug-induced as well as idiopathic lupus erythematosus.
  
  
  METHODS
  We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment. The condition resolved after adalimumab cessation, and the patient was started on ustekinumab with good results.
  
  
  CONCLUSIONS
  Ustekinumab might be a useful treatment option for patients with a history of TNF-induced lupus-like syndrome.
authors.affiliation: Department of Dermatology and Venereology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.
authors.forename: I
authors.initials: I
authors.lastname: Lomicová
authors.affiliation: Department of Clinical Pharmacology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.
authors.forename: D
authors.initials: D
authors.lastname: Suchý
authors.affiliation: Department of Dermatology and Venereology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.
authors.forename: K
authors.initials: K
authors.lastname: Pizinger
authors.affiliation: Department of Dermatology and Venereology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.
authors.forename: P
authors.initials: P
authors.lastname: Cetkovská
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab; D000068879:Adalimumab
keywords: anti-TNF treatment; drug-induced lupus erythematosus; lupus-like syndrome; ustekinumab